CompanyTBPHNasdaqGeorge Town, Grand Cayman, CA

Theravance Biopharma

Theravance Biopharma develops inhalation therapies for respiratory diseases.

SEC EDGAR ClinicalTrials.gov

8-KOct 1Latest SEC filing

Oct 1Latest story

September 2026

Zymeworks closes acquisition of Theravance Biopharma

Sep 23M&ATheravance Biopharma Zymeworks Inc.

Zymeworks-Theravance merger CVR agreement details milestone and royalty terms

Sep 23PartnershipTheravance Biopharma

COPD Foundation registers DELIVERY trial with Viatris, PARI, Theravance as collaborators

Sep 14Trial updateTheravance Biopharma

August 2026

Theravance Biopharma reports Q2 2026 results, confirms Zymeworks deal on track for second half close

Aug 10Quarterly updateTheravance Biopharma

June 2026

Zymeworks-Theravance merger includes new CVR tied to ampreloxetine monetization

Jun 29Regulatory decisionTheravance Biopharma Zymeworks Inc.

Zymeworks to acquire Theravance Biopharma for $17.00 per share plus CVR

Jun 29PartnershipTheravance Biopharma